20210916. Evopoint, SinoMab and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Shanghai, China — September XX, 2021 — Evopoint Biosesciences Co., Ltd.(“Evopoint”) announced with (HKEX 3681.HK, “SinoMab”) today that theyhave entered into an exclusive licensing agreement with (HKEX 1952.HK, “Everest”)to out-license the right to develop and commercialize XNW1011 (referred as “SN1011”by Sinomab), a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, toEverest globally for the treatment of renal diseases.
Under the termsof the agreement, Evopoint and SinoMab will receive USD $12 million in initialupfront payments from Everest and up to $549 million as future development,regulatory, and commercial milestone payments, as well as high single-digit tolow double-digit royalties on global net sales.
XNW1011is a next-generation covalent reversible BTK inhibitor. This asset is discovered by Evopoint independently, and currentlybeing developed for oncology conditions by Evopoint and collaborating with SinoMab for autoimmunediseases. Based on its excellent safety and pharmacokinetic characteristics observedin recently completed phase I trial with healthy subjects, XNW1011 is expectedto have great potential to treat a wider range of diseases over other BTKinhibitors. Phase II trials of XNW1011 in multiple indications are being plannedby both Evopoint and SinoMab.
“Since the founding of Evopoint in 2017, we have establisheda highly capable R&D organization and an innovative and differentiated pipeline.”said Jason Meijie Le, chief executive officer of Evopoint. “This alliance withEverest is not only recognition of the potential of XNW1011 as next-generation BTKinhibitor, but also recognition of our vision to continuously innovate and ourability to execute. We are delighted toreach this collaboration with Everest, who shares the same vision and commitmentto accelerate drug development. We look forward to working with Everest andother partners to develop XNW1011 and more novel therapies for patientssuffering from many debilitating diseases, not only in China but also aroundthe world”
About Evopoint
Evopoint is a global biopharmaceutical company focused on discovery,development, and commercialization of innovative medicines to address significant unmet clinical needs. Headquartered in Suzhou,China, the Company has established a highly efficient, fully integrated global R&Dorganization with presence in China, US and Australia. Leveraging our scientific expertise andproprietary discovery platforms, Evopoint has developed a robust and balancedpipeline, which consists of five first-in-class or best-in-class clinicalprograms and many more preclinical programs. The Company’s diseases areasof focus include oncology, metabolic and infectious diseases. For more information, please visit its websiteat www.chengjiafs.com
AboutSinoMab Biosescience Limited
SinoMab Biosescience Limited (HKEX:3681.HK) is dedicated to the research, development, manufacturing andcommercialization of therapeutics for the treatment of immunological diseases.The Company’s flagship product SM03 is a potential global first-in-target mAbagainst CD22 for the treatment of rheumatoid arthritis and is currently inPhase III clinical trial for rheumatoid arthritis in China, which has beenrecognized as one of the significant special projects of Significant New DrugsDevelopment of the Twelfth Five-Year Plan Period and the Thirteenth Five-YearPlan Period. In addition, the Company possesses other potential first-in-targetand first-in-class drug candidates, some of which are already in clinicalstage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus,pemphigus vulgaris, non-Hodgkin'slymphoma, asthma, and other diseases with major unmet clinical needs.
About EverestMedicines
EverestMedicines is a biopharmaceutical company focused on developing andcommercializing transformative pharmaceutical products that address criticalunmet medical needs for patients in Greater China and other Asian markets. Themanagement team of Everest Medicines has deep expertise and an extensive trackrecord of high-quality clinical development, regulatory affairs, CMC, businessdevelopment and operations both in China and with leading global pharmaceuticalcompanies. Everest Medicines has built a portfolio of eight potentially globalfirst-in-class or best-in-class molecules, many of which are in late stage clinicaldevelopment. The Company’s therapeutic areas of interest include oncology,autoimmune disorders, cardio-renal diseases and infectious diseases. For moreinformation, please visit its website at www.everestmedicines.com.
